Digoxin Tablets Recalled Due to Cross Contamination with Mycophenolate Mofetil
Novitium Pharma LLC recalls Digoxin 125mcg tablets nationwide due to cross contamination with mycophenolate mofetil, a different medication. Patients receiving contaminated tablets could experience unintended drug effects.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Cross contamination with mycophenolate mofetil, a different pharmaceutical product, represents a risk-of-harm situation as patients may receive an incorrect medication with different therapeutic effects. This warrants a High severity score per the rubric, despite the FDA Class III classification.
Plain-English summary
Digoxin Tablets, USP 125 micrograms (0.125 mg) manufactured by Novitium Pharma LLC in 1000-count bottles are being recalled. The recall involves Lot #M23172A, expiring January 31, 2025. A total of 3,940 bottles have been recalled.
The recall was initiated due to cross contamination with mycophenolate mofetil, another pharmaceutical product. Digoxin and mycophenolate mofetil are different medications with different therapeutic purposes.
The recalled product was distributed nationwide in the USA.
Patients currently taking digoxin from the affected lot should immediately contact their pharmacy or healthcare provider to verify they are not using the recalled product. Patients should not discard their medication or change their treatment regimen without consulting a healthcare provider.
The recalled product
- Product
- DIGOXIN (DIGOXIN)
- Brand
- DIGOXIN
- Manufacturer
- Novitium Pharma LLC
- Category
- Drug
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: M23172A
- Exp 01/31/2025
UPCs (4)
- 0370954201106
- 0370954201205
- 0370954202103
- 0370954200109
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DIGOXIN
- ModerateDigoxin Tablets Recalled Due to Failed Impurity and Degradation Specifications
FDA (Drugs) · 2024-04-24
Same manufacturer · Novitium Pharma LLC
See all →- SevereNovitium Pharma Recalls Ranitidine Capsules Due to NDMA Impurity
FDA (Drugs) · 2019-11-20
- SevereNovitium Pharma Recalls Ranitidine Capsules Due to NDMA Impurity
FDA (Drugs) · 2019-11-20
- SevereNovitium Pharma Recalls Ranitidine Capsules Due to NDMA Impurity
FDA (Drugs) · 2019-11-20
- SevereNovitium Pharma Recalls Ranitidine Capsules Due to NDMA Impurity
FDA (Drugs) · 2019-11-20
Same hazard · cross contamination
See all →- CriticalCetirizine Hydrochloride Tablets Recalled Due to Cross Contamination with Ranitidine
FDA (Drugs) · 2026-07-29
- ModeratePrimidone tablets recalled over potential acemetacin cross-contamination at API manufacturer
FDA (Drugs) · 2026-06-17
- HighFly By Jing creamy sesame noodles may contain undeclared peanut
FDA (Food) · 2026-06-03
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets 50 mg Recalled for API Cross-Contamination
FDA (Drugs) · 2026-05-27